Why OnKure Therapeutics, Inc.’s (OKUR) Stock Is Up 5.01%
As of Monday, August 17, OnKure Therapeutics, Inc.’s OKUR share price has surged by 5.01%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in Boulder, Colorado.
Commentary & Analysis
Why OnKure Therapeutics, Inc.’s (OKUR) Stock Is Down 5.36%
As of Wednesday, August 05, OnKure Therapeutics, Inc.’s OKUR share price has dipped by 5.36%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why OnKure Therapeutics, Inc.’s (OKUR) Stock Is Up 7.55%
As of Tuesday, August 04, OnKure Therapeutics, Inc.’s OKUR share price has surged by 7.55%, which has investors questioning if this is right time to sell.Michael Rose
Why OnKure Therapeutics, Inc.’s (OKUR) Stock Is Down 6.00%
As of Friday, July 31, OnKure Therapeutics, Inc.’s OKUR share price has dipped by 6.00%, which has investors questioning if this is right time to buy.Michael Rose
Why OnKure Therapeutics, Inc.’s (OKUR) Stock Is Down 5.04%
As of Friday, July 10, OnKure Therapeutics, Inc.’s OKUR share price has dipped by 5.04%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Financial Summary
| Share Statistics | OKUR | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $143.4 | $288.9 | 24% |
|
| Shares Out (Mil) | 49.9 | 54.0 | 47% |
|
| Institutional Ownership | 83.3% | 93.1% | 51% |
|
| Float (Mil) | 21.4 | 41.4 | 30% |
|
| Beta | na | 0.94 | na |
|
| Avg Daily Volume (000s) | 173 | 480 | 44% |
|
| Price Change (52-week) |
27.8% | 59.9% | 69% |
|
| Growth | OKUR | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | na | (10.1%) | na |
|
| EPS (5yr) | na | 15.9% | na |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | na | (15.6%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 4 | 4 | 3 | |
| Current EPS | ($0.410) | ($1.830) | ($1.527) | |
| Month Ago EPS | ($0.535) | ($2.363) | ($2.130) | |
| # Rev Up | 2 | 0 | 0 | |
| # Rev Down | 0 | 2 | 2 | |
| Three Months Ago EPS | ($0.573) | ($2.503) | ($2.130) | |
| Year/Year Chg | 33.1% | (58.4%) | (62.4%) | |
| Financials | OKUR | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($59) | ($43) | 15% |
|
| EPS (TTM) | ($2.584) | ($1.500) | 12% |
|
| Operating Cash Flow (TTM) (Mil) | ($48) | ($31) | 10% |
|
| Net Cash Flow (TTM) (Mil) | $83 | $2 | 75% |
|
| Long-Term Debt (Q1) (Mil) | $1 | $4 | 15% |
|
| Enterprise Value (Q1) (Mil) | ($22) | $190 | 1% |
|
| Valuation | OKUR | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.83 | 2.84 | 16% |
|
| P/E | na | 20.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | OKUR | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (44.2%) | (47.7%) | 13% |
|
| ROE | (46.9%) | (55.0%) | 16% |
|
| Liabilities to Assets | 4.0% | 29.6% | 2% |
|
| F-Score | 4 | 3 | 33% |
|
OnKure Therapeutics, Inc. did not pass any screens on 9/2/2026.
